Alnylam Pharmaceuticals
ALNY
#637
Rank
โ‚ฌ26.68 B
Marketcap
206,20ย โ‚ฌ
Share price
1.76%
Change (1 day)
51.39%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -3,77ย โ‚ฌ

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -3,61ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of -8,17ย โ‚ฌ a decrease over its 2021 EPS that were of -6,33ย โ‚ฌ.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-3,77ย โ‚ฌ-53.85%
2022-8,17ย โ‚ฌ29.03%
2021-6,33ย โ‚ฌ-3.36%
2020-6,55ย โ‚ฌ-8.48%
2019-7,16ย โ‚ฌ7.67%
2018-6,65ย โ‚ฌ39.74%
2017-4,76ย โ‚ฌ12.94%
2016-4,21ย โ‚ฌ38.84%
2015-3,03ย โ‚ฌ-32.88%
2014-4,52ย โ‚ฌ259.44%
2013-1,26ย โ‚ฌ-31.25%
2012-1,83ย โ‚ฌ52.94%
2011-1,20ย โ‚ฌ30.77%
2010-0,91ย โ‚ฌ-8.77%
2009-1,00ย โ‚ฌ78.13%
2008-0,56ย โ‚ฌ-70.78%
2007-1,93ย โ‚ฌ99.09%
2006-0,97ย โ‚ฌ-43.88%
2005-1,72ย โ‚ฌ-82.33%
2004-9,75ย โ‚ฌ-59.23%
2003-23,92ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-1,49ย โ‚ฌ-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
32,84ย โ‚ฌ-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-6,88ย โ‚ฌ 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,24ย โ‚ฌ-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-1,49ย โ‚ฌ-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
3,29ย โ‚ฌ-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
2,80ย โ‚ฌ-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-1,76ย โ‚ฌ-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel